At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 415 enrolled
Drug / intervention
TAK-272 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
In Brief
A Phase 2 clinical trial evaluating TAK-272, TAK-272 Placebo, and 2 other interventions for Type 2 Diabetes Mellitus and Microalbuminuria. Completed, enrolled 415 participants across 68 sites.
Detailed Summary
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind, placebo-controlled, parallel-group comparison in order to determine the clinical dose of TAK-272.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedJan 2015
Primary CompletionAug 2016
TodayJul 2026
First PostedJan 7, 2015
Enrollment StartOct 16, 2014
Primary CompletionAug 18, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.5 years ago
Interventions
TAK-272drug
TAK-272 tablets
TAK-272 Placebodrug
TAK-272 placebo-matching tablets
Candesartan cilexetildrug
Candesartan cilexetil tablets
Candesartan cilexetil Placebodrug
Candesartan cilexetil placebo-matching tablets